Updated Jul 16, 2026
Navratil Tomas has filed 3 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $1.14M.
Tomas Navratil is the Chief Development Officer at Glaukos Corp, a company specializing in ophthalmic pharmaceuticals and medical technology. He has been involved in various SEC filings related to the company's development activities.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-09 | GKOS | GLAUKOS Corp | S — Open-market sale | 716 | $139.06 | $100K |
| 2026-06-29 | GKOS | GLAUKOS Corp | F — Tax withholding / forfeiture | 483 | $142.57 | $69K |
| 2026-06-18 | GKOS | GLAUKOS Corp | S — Open-market sale | 1.5K | $130.68 | $201K |
| 2026-04-14 | GKOS | GLAUKOS Corp | S — Open-market sale [10b5-1] | 32 | $120.23 | $4K |
| 2026-04-14 | GKOS | GLAUKOS Corp | S — Open-market sale [10b5-1] | 614 | $119.35 | $73K |
| 2026-04-14 | GKOS | GLAUKOS Corp | S — Open-market sale [10b5-1] | 210 | $117.45 | $25K |
| 2026-04-14 | GKOS | GLAUKOS Corp | S — Open-market sale [10b5-1] | 1.2K | $116.72 | $144K |
| 2026-04-04 | GKOS | GLAUKOS Corp | F — Tax withholding / forfeiture | 1.8K | $109.60 | $201K |
| 2026-04-04 | GKOS | GLAUKOS Corp | F — Tax withholding / forfeiture | 1.1K | $109.60 | $126K |
| 2026-04-02 | GKOS | GLAUKOS Corp | F — Tax withholding / forfeiture | 5.8K | $109.60 | $635K |
| 2026-03-28 | GKOS | GLAUKOS Corp | A — Grant or award | 12.8K | $0.00 | |
| 2026-03-28 | GKOS | GLAUKOS Corp | A — Grant or award | 3.7K | $0.00 | |
| 2026-03-28 | GKOS | GLAUKOS Corp | A — Grant or award | 11.7K | $0.00 | |
| 2026-03-28 | GKOS | GLAUKOS Corp | A — Grant or award | 4.6K | $0.00 | |
| 2026-03-26 | GKOS | GLAUKOS Corp | F — Tax withholding / forfeiture | 2.5K | $105.23 | $268K |
| 2026-03-26 | GKOS | GLAUKOS Corp | F — Tax withholding / forfeiture | 2.6K | $106.84 | $281K |
| 2026-03-19 | GKOS | GLAUKOS Corp | S — Open-market sale [10b5-1] | 272 | $99.05 | $27K |
| 2026-03-19 | GKOS | GLAUKOS Corp | S — Open-market sale [10b5-1] | 299 | $98.21 | $29K |
| 2026-03-19 | GKOS | GLAUKOS Corp | S — Open-market sale [10b5-1] | 460 | $97.33 | $45K |
| 2026-03-19 | GKOS | GLAUKOS Corp | F — Tax withholding / forfeiture [10b5-1] | 958 | $98.94 | $95K |
Tomas Navratil is the Chief Development Officer at Glaukos Corp, a company specializing in ophthalmic pharmaceuticals and medical technology. He has been involved in various SEC filings related to the company's development activities.…
3 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 14 open-market sales ($1.14M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Navratil Tomas profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.